Feb. 22 at 5:58 AM
$SIGA
This is per the latest Federal Register notice (published). RRPV is a major collaborative research group focused on rapid medical countermeasure development—think biodefense, emerging infectious diseases, and fast-response tech against threats like pandemics or bioterror.
SIGA (makers of TPOXX, the key oral antiviral for smallpox approved by FDA and stockpiled by the US gov) joining this elite group (with dozens of biotechs, pharma, universities, and orgs like Johns Hopkins, Grifols, Paratek, etc.) means:
- Access to collaborative R&D projects, likely funded or supported by BARDA/HHS for rapid-response countermeasures.
- Antitrust protections under the National Cooperative Research Act → easier team-ups without legal headaches.
- Potential new contracts, partnerships, or funding streams in biodefense/emerging threats space—aligns perfectly with SIGA's core expertise in antivirals.
This strengthens SIGA's position in gov stockpiling & pandemic preparedness. Bullish signal
